Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
View original at globenewswire.comMenarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Myelofibrosis incidence is approximately 1-2 per 100,000 individuals per year, and median survival after diagnosis is six years
60% confidenceMenarini Group has a turnover of $5.5 billion, over 17,000 employees, 18 production sites, 9 R&D centers, and products available in 140 countries
60% confidenceSENTRY met its first co-primary endpoint: selinexor plus ruxolitinib achieved SVR35 of 49.8% vs 28.0% for ruxolitinib alone at week 24, a statistically significant improvement
60% confidenceConsistent SVR35 benefit was observed across prespecified subgroups, including patients receiving less than 15 mg of ruxolitinib per day
60% confidenceVariant allele frequency (VAF) reduction was observed in 32% of patients in the selinexor plus ruxolitinib arm vs 23.9% in the ruxolitinib alone arm at week 24, indicating potential for disease modification
60% confidenceThe selinexor plus ruxolitinib combination demonstrated a manageable safety and tolerability profile consistent with known individual profiles of selinexor and ruxolitinib, with no new safety signals observed
60% confidenceThe strength of the spleen response and encouraging early overall survival data from SENTRY creates hope for a potential new treatment option for myelofibrosis patients
60% confidenceSENTRY did not meet the second co-primary endpoint (Abs-TSS): combination arm showed 9.9 point improvement vs 10.9 point improvement for ruxolitinib alone at week 24, with no statistically significant difference between arms
60% confidenceEarly overall survival data from SENTRY showed greater than 50% reduction in risk of death for patients receiving selinexor combination versus ruxolitinib alone, with hazard ratio of 0.43
60% confidencePost-hoc analysis from Phase 3 SENTRY and new Phase 1 SENTRY data suggest SVR35 may predict overall survival
60% confidenceSpleen reduction is the essential goal of myelofibrosis treatment, and SENTRY's rapid, deep and durable results are associated with potential overall survival benefit and represent a potential new therapeutic advance
60% confidence